In conjunction with the reported clinical studies, immunotherapy targeting PD-1/PD-L1 or CTLA-4 has demonstrated limited efficacy against pancreatic cancer if not selected using suitable biomarkers17,18,26, and shown potential only in a small subset of patients33. Here, PDCD1 is linked to pancreatic neoplasm.